The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cardiac outcomes in women receiving aromatase inhibitors as adjuvant endocrine therapy for breast cancer.
Esther Park
No relevant relationships to disclose
Maysa M. Abu-Khalaf
Research Funding - Novartis
Christos Hatzis
No relevant relationships to disclose
Johanna M. LaSala
Stock Ownership - Biogen Idec (B); Bristol-Myers Squibb (B); Celgene (B); Gilead Sciences (B); Merck (B); Pfizer (B); Sanofi (B)
Andrea Silber
No relevant relationships to disclose
Erin Wysong Hofstatter
No relevant relationships to disclose
Tara Beth Sanft
No relevant relationships to disclose
Raymond Russell
No relevant relationships to disclose